伊布康唑对氟康唑敏感和耐药的外阴阴道念珠菌病女性分离株的 pH 活性。
pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Isolates from Women with Vulvovaginal Candidiasis.
机构信息
Wayne State University School of Medicine, Detroit, Michigan, USA.
SCYNEXIS, Inc., Jersey City, New Jersey, USA.
出版信息
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0056221. doi: 10.1128/AAC.00562-21.
Abstract
The vaginal environment with candidiasis has a pH of 3.8 to 4.5 and this has a negative effect on the activity of antifungals. Ibrexafungerp was evaluated against 187 isolates, including fluconazole-sensitive and -resistant Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis with the media adjusted to pH 7.0 and pH 4.5. Ibrexafungerp MIC values were not adversely affected when tested at pH 4.5. Ibrexafungerp exhibited significant activity against all isolates at pH 4.5.
摘要
阴道念珠菌病环境的 pH 值为 3.8 至 4.5，这会对抗真菌药物的活性产生负面影响。伊布列凡肽评估了包括氟康唑敏感和耐药的白念珠菌、近平滑念珠菌、克柔念珠菌、近平滑念珠菌和热带念珠菌在内的 187 株分离株，培养基的 pH 值分别调整为 7.0 和 4.5。在 pH 4.5 下测试时，伊布列凡肽的 MIC 值不受影响。伊布列凡肽在 pH 4.5 时对所有分离株均表现出显著的活性。
相似文献
1
pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Isolates from Women with Vulvovaginal Candidiasis.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0056221. doi: 10.1128/AAC.00562-21.
2
In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method.
Clin Microbiol Infect. 2022 Jan;28(1):140.e1-140.e4. doi: 10.1016/j.cmi.2021.09.030. Epub 2021 Oct 4.
3
Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of : A European Study.
Front Cell Infect Microbiol. 2022 May 16;12:906563. doi: 10.3389/fcimb.2022.906563. eCollection 2022.
4
In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures.
Clin Microbiol Infect. 2021 Jun;27(6):915.e5-915.e8. doi: 10.1016/j.cmi.2021.02.006. Epub 2021 Feb 16.
5
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp.
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221123144. doi: 10.1177/23247096221123144.
6
Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
BMC Pregnancy Childbirth. 2020 May 6;20(1):266. doi: 10.1186/s12884-020-02963-3.
7
Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis.
Expert Opin Investig Drugs. 2020 Sep;29(9):893-900. doi: 10.1080/13543784.2020.1791820. Epub 2020 Aug 19.
8
Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant and Non- Species.
Infect Dis Obstet Gynecol. 2018 Feb 22;2018:7040498. doi: 10.1155/2018/7040498. eCollection 2018.
9
Activity of Ibrexafungerp (SCY-078) against Isolates as Determined by EUCAST Methodology and Comparison with Activity against and and with the Activities of Six Comparator Agents.
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02136-19.
10
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02611-18. Print 2019 May.
引用本文的文献
1
Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods.
JAC Antimicrob Resist. 2025 Mar 19;7(2):dlaf040. doi: 10.1093/jacamr/dlaf040. eCollection 2025 Apr.
2
Antifungal Testing of Vaginal Isolates in Pregnant Women: A Retrospective, Single-Center Study in Adana, Türkiye.
J Fungi (Basel). 2025 Jan 24;11(2):92. doi: 10.3390/jof11020092.
3
New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions.
J Fungi (Basel). 2024 Dec 15;10(12):871. doi: 10.3390/jof10120871.
4
A review of the fernane-type triterpenoids as anti-fungal drugs.
Front Pharmacol. 2024 Aug 21;15:1447450. doi: 10.3389/fphar.2024.1447450. eCollection 2024.
5
Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306.
J Womens Health (Larchmt). 2023 Feb;32(2):178-186. doi: 10.1089/jwh.2022.0132. Epub 2022 Oct 17.
6
Pathogenesis and virulence of .
Virulence. 2022 Dec;13(1):89-121. doi: 10.1080/21505594.2021.2019950.
7
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.
Drugs R D. 2022 Mar;22(1):9-13. doi: 10.1007/s40268-021-00376-x. Epub 2021 Dec 27.
8
Antifungal Susceptibility Testing: A Primer for Clinicians.
Open Forum Infect Dis. 2021 Sep 9;8(11):ofab444. doi: 10.1093/ofid/ofab444. eCollection 2021 Nov.
9
Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
BJOG. 2022 Feb;129(3):412-420. doi: 10.1111/1471-0528.16972. Epub 2021 Nov 8.
10
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Clin Infect Dis. 2022 Jun 10;74(11):1979-1985. doi: 10.1093/cid/ciab750.
本文引用的文献
1
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against .
Front Cell Infect Microbiol. 2021 Mar 11;11:642358. doi: 10.3389/fcimb.2021.642358. eCollection 2021.
2
and Mechanisms of Antifungal Resistance.
Antibiotics (Basel). 2020 Jun 9;9(6):312. doi: 10.3390/antibiotics9060312.
3
Vulvovaginal Candidiasis: A Current Understanding and Burning Questions.
J Fungi (Basel). 2020 Feb 25;6(1):27. doi: 10.3390/jof6010027.
4
Recurrent Vulvovaginal Candidiasis: An Immunological Perspective.
Microorganisms. 2020 Jan 21;8(2):144. doi: 10.3390/microorganisms8020144.
5
Ibrexafungerp: A novel oral glucan synthase inhibitor.
Med Mycol. 2020 Jul 1;58(5):579-592. doi: 10.1093/mmy/myz083.
6
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [C]SCY-078 in Albino and Pigmented Rats.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.02119-18. Print 2019 Feb.
7
An Update on the Roles of Non- Species in Vulvovaginitis.
J Fungi (Basel). 2018 Oct 31;4(4):121. doi: 10.3390/jof4040121.
8
Estimation of Direct Healthcare Costs of Fungal Diseases in the United States.
Clin Infect Dis. 2019 May 17;68(11):1791-1797. doi: 10.1093/cid/ciy776.
9
Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant and Non- Species.
Infect Dis Obstet Gynecol. 2018 Feb 22;2018:7040498. doi: 10.1155/2018/7040498. eCollection 2018.
10
Reduced Antifungal Susceptibility of Vulvovaginal Candida Species at Normal Vaginal pH Levels: Clinical Implications.
J Low Genit Tract Dis. 2018 Apr;22(2):152-158. doi: 10.1097/LGT.0000000000000383.
Zotero 插件